2020 M&A Annual Review

Morrison & Foerster is recognized for Life Sciences & Pharmaceutical Sector (International & Cross-Border) in the USA. Chambers Global 2020 Morrison & Foerster is recognized for an industry focus of Healthcare: Life Sciences. Legal 500 2020 ADICET BIO Morrison & Foerster represented Adicet Bio, Inc., a privately held, pre-clinical-stage biopharmaceutical company, in its definitive merger agreement with resTORbio, Inc. (Nasdaq: TORC) in an all-stock transaction to create a combined publicly traded biotechnology company focused on the advancement of Adicet’s technology. The company will operate under the name Adicet Bio, Inc. (Nasdaq: ACET), and pre-closing Adicet equityholders owned 75% of the combined company as a result of the merger. Adicet was founded in 2015 and is developing novel, off-the-shelf allogeneic immune cell therapies based on gamma delta T cells engineered with chimeric antigen receptors. Adicet’s lead candidate, ADI-001, targets non-Hodgkin’s lymphoma.